查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1867542

镰状细胞疾病药物：全球市场份额和排名、总收入和需求预测（2025-2031 年）

Sickle Cell Anemia Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 104 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024 年全球镰状细胞贫血症治疗市场规模估计为 40.67 亿美元，预计到 2031 年将达到 99.88 亿美元，在预测期（2025-2031 年）内复合年增长率为 13.7%。

镰状细胞疾病（SCD）是一种慢性遗传性血液疾病，由β-珠蛋白基因突变引起，导致产生一种称为镰状血红蛋白（HbS）的异常血红蛋白。在缺氧条件下，HbS会发生聚合，使红血球呈现僵硬的镰状。这些畸形细胞容易发生溶血，并可能阻塞血管，造成疼痛、贫血和器官损伤。治疗方法包括药物治疗（例如羟基脲、L-麸酰胺酸）、基因治疗、造血干细胞移植和支持治疗。

在全球范围内，镰状细胞疾病治疗领域的主要企业包括 Emmaus Medical、Theravia、Gamida Cell 和 GlycoMimetics。美洲占最大的市场份额，约占 55%，其次是欧洲和中东及非洲，各占 35% 以上。按产品类型划分，输血疗法是最大的细分市场，占市场份额的 35% 以上。依适应症划分，儿科占比最大，其次是成人。镰状细胞疾病治疗领域正在快速发展，大型製药公司（例如辉瑞、诺华和诺和诺德）正与专业生物技术公司（例如 bluebird bio、CRISPR Therapeutics、Imara 和 Emmaus Medical）进行联合投资。已通过核准的疗法涵盖了从 Emmaus 的 L-谷氨酰胺等小分子药物到 bluebird 的 Zynteglo 和 CRISPR/Vertex 的 Casgevi 等根治性基因疗法的治疗方法。扩大基因疗法的患者可及性、确保长期安全性以及改进干细胞移植的预处理通讯协定仍然是未来发展的重点。抗黏附疗法（糖蛋白模拟物）、一氧化氮调节剂（Prolong）和巨噬细胞标靶疗法（Modus）等新型疗法正在丰富开发平臺。在临床创新不断推进和监管政策支持下，该领域正从对症治疗转向功能性治愈，尤其惠及全球服务不足的人群。

本报告旨在按地区/国家、类型和应用对全球镰状细胞疾病药物市场进行全面分析，重点关注总收入、市场份额和主要企业的排名。

本报告以收益为准，以2024年为基准年，对镰状细胞疾病治疗药物市场规模、估算和预测进行了阐述，并涵盖了2020年至2031年的历史数据和预测数据。定量和定性分析将帮助读者制定镰状细胞疾病治疗药物的业务和成长策略，评估市场竞争，分析自身在当前市场中的地位，并做出明智的商业决策。

市场区隔

公司

  • Emmaus Medical
  • Theravia
  • Pfizer
  • Novartis
  • Bluebird Bio
  • Novo Nordisk
  • Gamida Cell
  • CRISPR Therapeutics
  • GlycoMimetics
  • Prolong Pharmaceuticals
  • Modus Therapeutics
  • Sangamo Biosciences
  • Bioverativ
  • Imara
  • Ironwood Pharmaceuticals

按类型分類的细分市场

  • 输血疗法
  • 药物治疗
  • 骨髓移植

应用领域

  • 孩子们
  • 成人

按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 东南亚
    • 印度
    • 澳洲
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 荷兰
    • 北欧国家
    • 其他欧洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中东和非洲
    • 土耳其
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他中东和非洲地区

The global market for Sickle Cell Anemia Therapeutics was estimated to be worth US$ 4067 million in 2024 and is forecast to a readjusted size of US$ 9988 million by 2031 with a CAGR of 13.7% during the forecast period 2025-2031.

Sickle cell disease (SCD) is a chronic, inherited blood disorder caused by a mutation in the beta-globin gene, leading to the production of abnormal hemoglobin called sickle hemoglobin (HbS). Under low-oxygen conditions, HbS polymerizes, causing red blood cells to assume a rigid, sickle shape. These deformed cells are prone to hemolysis and can block blood vessels, resulting in pain, anemia, and organ damage. Therapeutic approaches include pharmacological treatments (e.g., hydroxyurea, L-glutamine), gene therapy, hematopoietic stem cell transplantation, and supportive care.

Global Sickle Cell Anemia Therapeutics key players include Emmaus Medical, Theravia, Gamida Cell, GlycoMimetics, etc. Americas is the largest market, with a share about 55%, followed by Europe, and Middle East & Africa, both have a share over 35 percent. In terms of product, Blood Transfusion is the largest segment, with a share over 35%. And in terms of application, the largest application is Child, followed by Adult.The therapeutic landscape for sickle cell disease is rapidly evolving, with major pharmaceutical players (e.g., Pfizer, Novartis, Novo Nordisk) investing alongside specialized biotech firms (e.g., Bluebird Bio, CRISPR Therapeutics, Imara, Emmaus Medical). Approved treatments range from small-molecule agents like L-glutamine (Emmaus) to gene-based curative approaches such as Bluebird's Zynteglo and CRISPR/Vertex's Casgevy, marking a shift toward durable, potentially one-time interventions. Future development will prioritize expanding patient access to gene therapies, addressing long-term safety, and improving conditioning regimens for stem cell transplantation. Novel approaches, including anti-adhesion therapies (GlycoMimetics), nitric oxide modulators (Prolong), and macrophage-targeted solutions (Modus), are diversifying the pipeline. With ongoing clinical innovation and supportive regulatory momentum, the field is transitioning from symptomatic relief to functional cures, especially for underserved global populations.

This report aims to provide a comprehensive presentation of the global market for Sickle Cell Anemia Therapeutics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Sickle Cell Anemia Therapeutics by region & country, by Type, and by Application.

The Sickle Cell Anemia Therapeutics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Sickle Cell Anemia Therapeutics.

Market Segmentation

By Company

  • Emmaus Medical
  • Theravia
  • Pfizer
  • Novartis
  • Bluebird Bio
  • Novo Nordisk
  • Gamida Cell
  • CRISPR Therapeutics
  • GlycoMimetics
  • Prolong Pharmaceuticals
  • Modus Therapeutics
  • Sangamo Biosciences
  • Bioverativ
  • Imara
  • Ironwood Pharmaceuticals

Segment by Type

  • Blood Transfusion
  • Pharmacotherapy
  • Bone Marrow Transplant

Segment by Application

  • Child
  • Adult

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Sickle Cell Anemia Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Sickle Cell Anemia Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Sickle Cell Anemia Therapeutics in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Sickle Cell Anemia Therapeutics Product Introduction
  • 1.2 Global Sickle Cell Anemia Therapeutics Market Size Forecast (2020-2031)
  • 1.3 Sickle Cell Anemia Therapeutics Market Trends & Drivers
    • 1.3.1 Sickle Cell Anemia Therapeutics Industry Trends
    • 1.3.2 Sickle Cell Anemia Therapeutics Market Drivers & Opportunity
    • 1.3.3 Sickle Cell Anemia Therapeutics Market Challenges
    • 1.3.4 Sickle Cell Anemia Therapeutics Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Sickle Cell Anemia Therapeutics Players Revenue Ranking (2024)
  • 2.2 Global Sickle Cell Anemia Therapeutics Revenue by Company (2020-2025)
  • 2.3 Key Companies Sickle Cell Anemia Therapeutics Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Sickle Cell Anemia Therapeutics Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Sickle Cell Anemia Therapeutics
  • 2.6 Sickle Cell Anemia Therapeutics Market Competitive Analysis
    • 2.6.1 Sickle Cell Anemia Therapeutics Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Sickle Cell Anemia Therapeutics Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Sickle Cell Anemia Therapeutics as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Blood Transfusion
    • 3.1.2 Pharmacotherapy
    • 3.1.3 Bone Marrow Transplant
  • 3.2 Global Sickle Cell Anemia Therapeutics Sales Value by Type
    • 3.2.1 Global Sickle Cell Anemia Therapeutics Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Sickle Cell Anemia Therapeutics Sales Value, by Type (2020-2031)
    • 3.2.3 Global Sickle Cell Anemia Therapeutics Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Child
    • 4.1.2 Adult
  • 4.2 Global Sickle Cell Anemia Therapeutics Sales Value by Application
    • 4.2.1 Global Sickle Cell Anemia Therapeutics Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Sickle Cell Anemia Therapeutics Sales Value, by Application (2020-2031)
    • 4.2.3 Global Sickle Cell Anemia Therapeutics Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Sickle Cell Anemia Therapeutics Sales Value by Region
    • 5.1.1 Global Sickle Cell Anemia Therapeutics Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Sickle Cell Anemia Therapeutics Sales Value by Region (2020-2025)
    • 5.1.3 Global Sickle Cell Anemia Therapeutics Sales Value by Region (2026-2031)
    • 5.1.4 Global Sickle Cell Anemia Therapeutics Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Sickle Cell Anemia Therapeutics Sales Value, 2020-2031
    • 5.2.2 North America Sickle Cell Anemia Therapeutics Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Sickle Cell Anemia Therapeutics Sales Value, 2020-2031
    • 5.3.2 Europe Sickle Cell Anemia Therapeutics Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Sickle Cell Anemia Therapeutics Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Sickle Cell Anemia Therapeutics Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Sickle Cell Anemia Therapeutics Sales Value, 2020-2031
    • 5.5.2 South America Sickle Cell Anemia Therapeutics Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Sickle Cell Anemia Therapeutics Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Sickle Cell Anemia Therapeutics Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Sickle Cell Anemia Therapeutics Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Sickle Cell Anemia Therapeutics Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Sickle Cell Anemia Therapeutics Sales Value, 2020-2031
    • 6.3.2 United States Sickle Cell Anemia Therapeutics Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Sickle Cell Anemia Therapeutics Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Sickle Cell Anemia Therapeutics Sales Value, 2020-2031
    • 6.4.2 Europe Sickle Cell Anemia Therapeutics Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Sickle Cell Anemia Therapeutics Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Sickle Cell Anemia Therapeutics Sales Value, 2020-2031
    • 6.5.2 China Sickle Cell Anemia Therapeutics Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Sickle Cell Anemia Therapeutics Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Sickle Cell Anemia Therapeutics Sales Value, 2020-2031
    • 6.6.2 Japan Sickle Cell Anemia Therapeutics Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Sickle Cell Anemia Therapeutics Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Sickle Cell Anemia Therapeutics Sales Value, 2020-2031
    • 6.7.2 South Korea Sickle Cell Anemia Therapeutics Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Sickle Cell Anemia Therapeutics Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Sickle Cell Anemia Therapeutics Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Sickle Cell Anemia Therapeutics Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Sickle Cell Anemia Therapeutics Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Sickle Cell Anemia Therapeutics Sales Value, 2020-2031
    • 6.9.2 India Sickle Cell Anemia Therapeutics Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Sickle Cell Anemia Therapeutics Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Emmaus Medical
    • 7.1.1 Emmaus Medical Profile
    • 7.1.2 Emmaus Medical Main Business
    • 7.1.3 Emmaus Medical Sickle Cell Anemia Therapeutics Products, Services and Solutions
    • 7.1.4 Emmaus Medical Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Emmaus Medical Recent Developments
  • 7.2 Theravia
    • 7.2.1 Theravia Profile
    • 7.2.2 Theravia Main Business
    • 7.2.3 Theravia Sickle Cell Anemia Therapeutics Products, Services and Solutions
    • 7.2.4 Theravia Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.2.5 Theravia Recent Developments
  • 7.3 Pfizer
    • 7.3.1 Pfizer Profile
    • 7.3.2 Pfizer Main Business
    • 7.3.3 Pfizer Sickle Cell Anemia Therapeutics Products, Services and Solutions
    • 7.3.4 Pfizer Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Pfizer Recent Developments
  • 7.4 Novartis
    • 7.4.1 Novartis Profile
    • 7.4.2 Novartis Main Business
    • 7.4.3 Novartis Sickle Cell Anemia Therapeutics Products, Services and Solutions
    • 7.4.4 Novartis Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.4.5 Novartis Recent Developments
  • 7.5 Bluebird Bio
    • 7.5.1 Bluebird Bio Profile
    • 7.5.2 Bluebird Bio Main Business
    • 7.5.3 Bluebird Bio Sickle Cell Anemia Therapeutics Products, Services and Solutions
    • 7.5.4 Bluebird Bio Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.5.5 Bluebird Bio Recent Developments
  • 7.6 Novo Nordisk
    • 7.6.1 Novo Nordisk Profile
    • 7.6.2 Novo Nordisk Main Business
    • 7.6.3 Novo Nordisk Sickle Cell Anemia Therapeutics Products, Services and Solutions
    • 7.6.4 Novo Nordisk Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.6.5 Novo Nordisk Recent Developments
  • 7.7 Gamida Cell
    • 7.7.1 Gamida Cell Profile
    • 7.7.2 Gamida Cell Main Business
    • 7.7.3 Gamida Cell Sickle Cell Anemia Therapeutics Products, Services and Solutions
    • 7.7.4 Gamida Cell Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.7.5 Gamida Cell Recent Developments
  • 7.8 CRISPR Therapeutics
    • 7.8.1 CRISPR Therapeutics Profile
    • 7.8.2 CRISPR Therapeutics Main Business
    • 7.8.3 CRISPR Therapeutics Sickle Cell Anemia Therapeutics Products, Services and Solutions
    • 7.8.4 CRISPR Therapeutics Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.8.5 CRISPR Therapeutics Recent Developments
  • 7.9 GlycoMimetics
    • 7.9.1 GlycoMimetics Profile
    • 7.9.2 GlycoMimetics Main Business
    • 7.9.3 GlycoMimetics Sickle Cell Anemia Therapeutics Products, Services and Solutions
    • 7.9.4 GlycoMimetics Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.9.5 GlycoMimetics Recent Developments
  • 7.10 Prolong Pharmaceuticals
    • 7.10.1 Prolong Pharmaceuticals Profile
    • 7.10.2 Prolong Pharmaceuticals Main Business
    • 7.10.3 Prolong Pharmaceuticals Sickle Cell Anemia Therapeutics Products, Services and Solutions
    • 7.10.4 Prolong Pharmaceuticals Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.10.5 Prolong Pharmaceuticals Recent Developments
  • 7.11 Modus Therapeutics
    • 7.11.1 Modus Therapeutics Profile
    • 7.11.2 Modus Therapeutics Main Business
    • 7.11.3 Modus Therapeutics Sickle Cell Anemia Therapeutics Products, Services and Solutions
    • 7.11.4 Modus Therapeutics Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.11.5 Modus Therapeutics Recent Developments
  • 7.12 Sangamo Biosciences
    • 7.12.1 Sangamo Biosciences Profile
    • 7.12.2 Sangamo Biosciences Main Business
    • 7.12.3 Sangamo Biosciences Sickle Cell Anemia Therapeutics Products, Services and Solutions
    • 7.12.4 Sangamo Biosciences Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.12.5 Sangamo Biosciences Recent Developments
  • 7.13 Bioverativ
    • 7.13.1 Bioverativ Profile
    • 7.13.2 Bioverativ Main Business
    • 7.13.3 Bioverativ Sickle Cell Anemia Therapeutics Products, Services and Solutions
    • 7.13.4 Bioverativ Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.13.5 Bioverativ Recent Developments
  • 7.14 Imara
    • 7.14.1 Imara Profile
    • 7.14.2 Imara Main Business
    • 7.14.3 Imara Sickle Cell Anemia Therapeutics Products, Services and Solutions
    • 7.14.4 Imara Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.14.5 Imara Recent Developments
  • 7.15 Ironwood Pharmaceuticals
    • 7.15.1 Ironwood Pharmaceuticals Profile
    • 7.15.2 Ironwood Pharmaceuticals Main Business
    • 7.15.3 Ironwood Pharmaceuticals Sickle Cell Anemia Therapeutics Products, Services and Solutions
    • 7.15.4 Ironwood Pharmaceuticals Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
    • 7.15.5 Ironwood Pharmaceuticals Recent Developments

8 Industry Chain Analysis

  • 8.1 Sickle Cell Anemia Therapeutics Industrial Chain
  • 8.2 Sickle Cell Anemia Therapeutics Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Sickle Cell Anemia Therapeutics Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Sickle Cell Anemia Therapeutics Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Sickle Cell Anemia Therapeutics Market Trends
  • Table 2. Sickle Cell Anemia Therapeutics Market Drivers & Opportunity
  • Table 3. Sickle Cell Anemia Therapeutics Market Challenges
  • Table 4. Sickle Cell Anemia Therapeutics Market Restraints
  • Table 5. Global Sickle Cell Anemia Therapeutics Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Sickle Cell Anemia Therapeutics Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies Sickle Cell Anemia Therapeutics Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies Sickle Cell Anemia Therapeutics Product Type
  • Table 9. Key Companies Time to Begin Mass Production of Sickle Cell Anemia Therapeutics
  • Table 10. Global Sickle Cell Anemia Therapeutics Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Sickle Cell Anemia Therapeutics as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global Sickle Cell Anemia Therapeutics Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global Sickle Cell Anemia Therapeutics Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global Sickle Cell Anemia Therapeutics Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global Sickle Cell Anemia Therapeutics Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global Sickle Cell Anemia Therapeutics Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global Sickle Cell Anemia Therapeutics Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global Sickle Cell Anemia Therapeutics Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global Sickle Cell Anemia Therapeutics Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global Sickle Cell Anemia Therapeutics Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global Sickle Cell Anemia Therapeutics Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global Sickle Cell Anemia Therapeutics Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global Sickle Cell Anemia Therapeutics Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global Sickle Cell Anemia Therapeutics Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global Sickle Cell Anemia Therapeutics Sales Value by Region (2020-2025) & (%)
  • Table 27. Global Sickle Cell Anemia Therapeutics Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions Sickle Cell Anemia Therapeutics Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions Sickle Cell Anemia Therapeutics Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions Sickle Cell Anemia Therapeutics Sales Value, (2026-2031) & (US$ Million)
  • Table 31. Emmaus Medical Basic Information List
  • Table 32. Emmaus Medical Description and Business Overview
  • Table 33. Emmaus Medical Sickle Cell Anemia Therapeutics Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in Sickle Cell Anemia Therapeutics Business of Emmaus Medical (2020-2025)
  • Table 35. Emmaus Medical Recent Developments
  • Table 36. Theravia Basic Information List
  • Table 37. Theravia Description and Business Overview
  • Table 38. Theravia Sickle Cell Anemia Therapeutics Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in Sickle Cell Anemia Therapeutics Business of Theravia (2020-2025)
  • Table 40. Theravia Recent Developments
  • Table 41. Pfizer Basic Information List
  • Table 42. Pfizer Description and Business Overview
  • Table 43. Pfizer Sickle Cell Anemia Therapeutics Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in Sickle Cell Anemia Therapeutics Business of Pfizer (2020-2025)
  • Table 45. Pfizer Recent Developments
  • Table 46. Novartis Basic Information List
  • Table 47. Novartis Description and Business Overview
  • Table 48. Novartis Sickle Cell Anemia Therapeutics Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in Sickle Cell Anemia Therapeutics Business of Novartis (2020-2025)
  • Table 50. Novartis Recent Developments
  • Table 51. Bluebird Bio Basic Information List
  • Table 52. Bluebird Bio Description and Business Overview
  • Table 53. Bluebird Bio Sickle Cell Anemia Therapeutics Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in Sickle Cell Anemia Therapeutics Business of Bluebird Bio (2020-2025)
  • Table 55. Bluebird Bio Recent Developments
  • Table 56. Novo Nordisk Basic Information List
  • Table 57. Novo Nordisk Description and Business Overview
  • Table 58. Novo Nordisk Sickle Cell Anemia Therapeutics Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in Sickle Cell Anemia Therapeutics Business of Novo Nordisk (2020-2025)
  • Table 60. Novo Nordisk Recent Developments
  • Table 61. Gamida Cell Basic Information List
  • Table 62. Gamida Cell Description and Business Overview
  • Table 63. Gamida Cell Sickle Cell Anemia Therapeutics Products, Services and Solutions
  • Table 64. Revenue (US$ Million) in Sickle Cell Anemia Therapeutics Business of Gamida Cell (2020-2025)
  • Table 65. Gamida Cell Recent Developments
  • Table 66. CRISPR Therapeutics Basic Information List
  • Table 67. CRISPR Therapeutics Description and Business Overview
  • Table 68. CRISPR Therapeutics Sickle Cell Anemia Therapeutics Products, Services and Solutions
  • Table 69. Revenue (US$ Million) in Sickle Cell Anemia Therapeutics Business of CRISPR Therapeutics (2020-2025)
  • Table 70. CRISPR Therapeutics Recent Developments
  • Table 71. GlycoMimetics Basic Information List
  • Table 72. GlycoMimetics Description and Business Overview
  • Table 73. GlycoMimetics Sickle Cell Anemia Therapeutics Products, Services and Solutions
  • Table 74. Revenue (US$ Million) in Sickle Cell Anemia Therapeutics Business of GlycoMimetics (2020-2025)
  • Table 75. GlycoMimetics Recent Developments
  • Table 76. Prolong Pharmaceuticals Basic Information List
  • Table 77. Prolong Pharmaceuticals Description and Business Overview
  • Table 78. Prolong Pharmaceuticals Sickle Cell Anemia Therapeutics Products, Services and Solutions
  • Table 79. Revenue (US$ Million) in Sickle Cell Anemia Therapeutics Business of Prolong Pharmaceuticals (2020-2025)
  • Table 80. Prolong Pharmaceuticals Recent Developments
  • Table 81. Modus Therapeutics Basic Information List
  • Table 82. Modus Therapeutics Description and Business Overview
  • Table 83. Modus Therapeutics Sickle Cell Anemia Therapeutics Products, Services and Solutions
  • Table 84. Revenue (US$ Million) in Sickle Cell Anemia Therapeutics Business of Modus Therapeutics (2020-2025)
  • Table 85. Modus Therapeutics Recent Developments
  • Table 86. Sangamo Biosciences Basic Information List
  • Table 87. Sangamo Biosciences Description and Business Overview
  • Table 88. Sangamo Biosciences Sickle Cell Anemia Therapeutics Products, Services and Solutions
  • Table 89. Revenue (US$ Million) in Sickle Cell Anemia Therapeutics Business of Sangamo Biosciences (2020-2025)
  • Table 90. Sangamo Biosciences Recent Developments
  • Table 91. Bioverativ Basic Information List
  • Table 92. Bioverativ Description and Business Overview
  • Table 93. Bioverativ Sickle Cell Anemia Therapeutics Products, Services and Solutions
  • Table 94. Revenue (US$ Million) in Sickle Cell Anemia Therapeutics Business of Bioverativ (2020-2025)
  • Table 95. Bioverativ Recent Developments
  • Table 96. Imara Basic Information List
  • Table 97. Imara Description and Business Overview
  • Table 98. Imara Sickle Cell Anemia Therapeutics Products, Services and Solutions
  • Table 99. Revenue (US$ Million) in Sickle Cell Anemia Therapeutics Business of Imara (2020-2025)
  • Table 100. Imara Recent Developments
  • Table 101. Ironwood Pharmaceuticals Basic Information List
  • Table 102. Ironwood Pharmaceuticals Description and Business Overview
  • Table 103. Ironwood Pharmaceuticals Sickle Cell Anemia Therapeutics Products, Services and Solutions
  • Table 104. Revenue (US$ Million) in Sickle Cell Anemia Therapeutics Business of Ironwood Pharmaceuticals (2020-2025)
  • Table 105. Ironwood Pharmaceuticals Recent Developments
  • Table 106. Key Raw Materials Lists
  • Table 107. Raw Materials Key Suppliers Lists
  • Table 108. Sickle Cell Anemia Therapeutics Downstream Customers
  • Table 109. Sickle Cell Anemia Therapeutics Distributors List
  • Table 110. Research Programs/Design for This Report
  • Table 111. Key Data Information from Secondary Sources
  • Table 112. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Sickle Cell Anemia Therapeutics Product Picture
  • Figure 2. Global Sickle Cell Anemia Therapeutics Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Sickle Cell Anemia Therapeutics Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Sickle Cell Anemia Therapeutics Report Years Considered
  • Figure 5. Global Sickle Cell Anemia Therapeutics Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Sickle Cell Anemia Therapeutics Revenue in 2024
  • Figure 7. Sickle Cell Anemia Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. Blood Transfusion Picture
  • Figure 9. Pharmacotherapy Picture
  • Figure 10. Bone Marrow Transplant Picture
  • Figure 11. Global Sickle Cell Anemia Therapeutics Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 12. Global Sickle Cell Anemia Therapeutics Sales Value Market Share by Type, 2024 & 2031
  • Figure 13. Product Picture of Child
  • Figure 14. Product Picture of Adult
  • Figure 15. Global Sickle Cell Anemia Therapeutics Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 16. Global Sickle Cell Anemia Therapeutics Sales Value Market Share by Application, 2024 & 2031
  • Figure 17. North America Sickle Cell Anemia Therapeutics Sales Value (2020-2031) & (US$ Million)
  • Figure 18. North America Sickle Cell Anemia Therapeutics Sales Value by Country (%), 2024 VS 2031
  • Figure 19. Europe Sickle Cell Anemia Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 20. Europe Sickle Cell Anemia Therapeutics Sales Value by Country (%), 2024 VS 2031
  • Figure 21. Asia Pacific Sickle Cell Anemia Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 22. Asia Pacific Sickle Cell Anemia Therapeutics Sales Value by Region (%), 2024 VS 2031
  • Figure 23. South America Sickle Cell Anemia Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 24. South America Sickle Cell Anemia Therapeutics Sales Value by Country (%), 2024 VS 2031
  • Figure 25. Middle East & Africa Sickle Cell Anemia Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 26. Middle East & Africa Sickle Cell Anemia Therapeutics Sales Value by Country (%), 2024 VS 2031
  • Figure 27. Key Countries/Regions Sickle Cell Anemia Therapeutics Sales Value (%), (2020-2031)
  • Figure 28. United States Sickle Cell Anemia Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 29. United States Sickle Cell Anemia Therapeutics Sales Value by Type (%), 2024 VS 2031
  • Figure 30. United States Sickle Cell Anemia Therapeutics Sales Value by Application (%), 2024 VS 2031
  • Figure 31. Europe Sickle Cell Anemia Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 32. Europe Sickle Cell Anemia Therapeutics Sales Value by Type (%), 2024 VS 2031
  • Figure 33. Europe Sickle Cell Anemia Therapeutics Sales Value by Application (%), 2024 VS 2031
  • Figure 34. China Sickle Cell Anemia Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 35. China Sickle Cell Anemia Therapeutics Sales Value by Type (%), 2024 VS 2031
  • Figure 36. China Sickle Cell Anemia Therapeutics Sales Value by Application (%), 2024 VS 2031
  • Figure 37. Japan Sickle Cell Anemia Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 38. Japan Sickle Cell Anemia Therapeutics Sales Value by Type (%), 2024 VS 2031
  • Figure 39. Japan Sickle Cell Anemia Therapeutics Sales Value by Application (%), 2024 VS 2031
  • Figure 40. South Korea Sickle Cell Anemia Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 41. South Korea Sickle Cell Anemia Therapeutics Sales Value by Type (%), 2024 VS 2031
  • Figure 42. South Korea Sickle Cell Anemia Therapeutics Sales Value by Application (%), 2024 VS 2031
  • Figure 43. Southeast Asia Sickle Cell Anemia Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 44. Southeast Asia Sickle Cell Anemia Therapeutics Sales Value by Type (%), 2024 VS 2031
  • Figure 45. Southeast Asia Sickle Cell Anemia Therapeutics Sales Value by Application (%), 2024 VS 2031
  • Figure 46. India Sickle Cell Anemia Therapeutics Sales Value, (2020-2031) & (US$ Million)
  • Figure 47. India Sickle Cell Anemia Therapeutics Sales Value by Type (%), 2024 VS 2031
  • Figure 48. India Sickle Cell Anemia Therapeutics Sales Value by Application (%), 2024 VS 2031
  • Figure 49. Sickle Cell Anemia Therapeutics Industrial Chain
  • Figure 50. Sickle Cell Anemia Therapeutics Manufacturing Cost Structure
  • Figure 51. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 52. Bottom-up and Top-down Approaches for This Report
  • Figure 53. Data Triangulation
  • Figure 54. Key Executives Interviewed